- Open Access
Systematic review regarding metabolic profiling for improved pathophysiological understanding of disease and outcome prediction in respiratory infections
Respiratory Research volume 16, Article number: 125 (2015)
Metabolic profiling through targeted quantification of a predefined subset of metabolites, performed by mass spectrometric analytical techniques, allows detailed investigation of biological pathways and thus may provide information about the interaction of different organic systems, ultimately improving understanding of disease risk and prognosis in a variety of diseases. Early risk assessment, in turn, may improve patient management in regard to cite-of-care decisions and treatment modalities. Within this review, we focus on the potential of metabolic profiling to improve our pathophysiological understanding of disease and management of patients. We focus thereby on lower respiratory tract infections (LRTI) including community-acquired pneumonia (CAP) and chronic obstructive pulmonary disease (COPD), an important disease responsible for high mortality, morbidity and costs worldwide. Observational data from numerous clinical and experimental studies have provided convincing data linking metabolic blood biomarkers such as lactate, glucose or cortisol to patient outcomes. Also, identified through metabolomic studies, novel innovative metabolic markers such as steroid hormones, biogenic amines, members of the oxidative status, sphingo- and glycerophospholipids, and trimethylamine-N-oxide (TMAO) have shown promising results. Since many uncertainties remain in predicting mortality in these patients, further prospective and retrospective observational studies are needed to uncover metabolic pathways responsible for mortality associated with LRTI. Improved understanding of outcome-specific metabolite signatures in LRTIs may optimize patient management strategies, provide potential new targets for future individual therapy, and thereby improve patients’ chances for survival.
The metabolome can be considered the “quantitative complement of all the low molecular weight molecules (<1500 amu) in a particular physiological or developmental state“ of a cell, tissue or organism . Metabolomics is defined as “the analysis of the whole metabolome under a given set of physiological, environmental and/or clinical conditions“ . Metabolite profiling through targeted quantification of a predefined subset of metabolites of the metabolome  allows analysis of metabolic pathways, thereby clarifying the interaction of different organic systems. While proteomics is the study of proteins made by the organism and the conditions under which the organism makes them, metabolomics is a more systematic study of the biochemical fingerprints that result of cellular processes.
Mass spectrometry (MS) is a sensitive tool that characterizes and quantifies metabolites in a biological sample . Since metabolomics requires proper separation of the different compounds to be analyzed, chemical separation techniques such as gas chromatography (GC) and liquid chromatography (LC) or capillary electrophoresis (CE) can be combined with MS detection. Analytical techniques such as LC-MS, GC-MS, CE-MS, and matrix-assisted laser desorption ionization-MS (MALDI-MS) may therefore expand coverage of the metabolome . MS is now a routine diagnostic instrument in clinical laboratories .
Biological information derived from these techniques can provide accurate and clinically useful diagnostic capability for the management of diseases [7, 8] by mapping disease risk to metabolic pathways . Previously, many studies have focused on risk prediction in patients with lower respiratory tract infections (LRTI) including community-acquired pneumonia (CAP) and case (COPD) because such information may have direct consequences in patient management [10–13]. Early risk prediction may improve site-of-care decisions (i.e., ICU treatment vs. hospital ward vs. outpatient) as well as treatment modalities (i.e., antibiotic drugs) [11, 14, 15]. Indeed, improved understanding of metabolic interactions in LRTI patients may enhance prediction of outcomes and provide targets for individual therapy, which in turn could facilitate personalized patient management (Fig. 2) [16–18].
Prediction of mortality in community-acquired pneumonia
CAP is the leading cause of infectious death , and of high mortality, morbidity, and costs worldwide [20–22]. Patients with CAP manifest high short-term mortality [23, 24] but also substantial long-term morbiditiy [25–28]. To predict all-cause mortality within 30 days, the pneumonia severity index (PSI) is a validated tool that categorizes CAP patients within distinct risk classes (I-V) . In Europe, the CURB-65 score (Confusion, Urea, Respiratory rate, Blood pressure, Age >65 years) is used for the same purpose . Several clinical studies show that measuring specific inflammatory or metabolic blood biomarkers, including among others proadrenomedullin (proADM) [14, 15, 31–33] and procalcitonin (PCT) [26, 34–36], provides prognostic information and possibly improves short-term risk stratification and management decisions in CAP compared to the use of clinical risk scores alone . Pneumonia not only increases short-term mortality; clinical trials also found greater long-term mortality rates in patients who survived an initial CAP episode, compared to the general population and to patients who have other infections [28, 38, 39]. These observations suggest that CAP is a poor prognostic indicator of long-term outcomes. Particularly, it has been hypothesized that cardiovascular events that are triggered by an episode of respiratory infection may be responsible for the excess mortality observed in large long-term CAP cohorts. For this reason, cardiovascular biomarkers (such as natriuretic peptides) may also help in the identification of high risk LRTI patients who need close monitoring and follow-up . The metabolomics approach for LRTI thus may also look into metabolites that have been linked to cardiovascular disease as these conditions are being linked very closely.
Prediction of mortality in patients hospitalized with exacerbated chronic obstructive pulmonary disease
Prediction of outcomes in chronic obstructive pulmonary disease (COPD) is challenging. Three published observational studies suggest that the inflammatory blood biomarker ProADM independently predicts medium-term all-cause mortality in patients with stable [40, 41] or exacerbated COPD. Additionally, measurement of ProADM combined with the clinical parameters of body mass index, airflow obstruction, dyspnea and exercise capacity index (BODE)  improves the predictive power of medium-term all-cause mortality compared to the use of BODE alone . A recent observational clinical cohort study demonstrated that ProADM levels are independent predictors of 5- to 7-year all-cause mortality, and may enhance long-term prognostic accuracy of demographic and clinical variables in patients hospitalized for exacerbation of pneumonic or non-pneumonic COPD . Similar to CAP, in COPD cardiovascular disease may be responsible for large portions of the high mortality associated with this disease. Again, the metabolomic approach in COPD may therefore also consider interesting metabolites associated with adverse cardiovascular outcomes.
Aims of the review and methodology
The goal of the present review is to investigate wether new metabolic blood biomarkers help optimizing identification of patients at risk for poor outcome in CAP and exacerbated COPD. We discuss nine metabolite classes: steroid hormones, biogenic amines, intermediate energy metabolism, monosaccharides, trimethylamines, oxidative status, sphingolipids, glycerophospholipids, and acylcarnitines. Each section will begin with a brief description of pathways and known physiological effects, followed by a summary of observational data regarding the analyte’s role in predicting all-cause mortality. We focus on patients with LRTI which is responsible for high mortality, morbidity and costs worldwide. Yet, if no data are available in strictly LRTI patients, we also discuss these markers in other diseases namely cardiovascular disease which may account for a large proportion of deaths attributable to LRTI.
Literature discussed in this review was in part identified through a systematic literature search of English-language publications indexed in PubMed in March 2015 under the terms “lower respiratory tract infection” or “pneumonia” or “chronic obstructive pulmonary disease” combined with “mortality” with or without “prediction” and/or “cardiovascular risk” together with any of the terms “steroid hormones” or “biogenic amines” or “trimethylamine-N-oxide” or “intermediates of energy metabolism” or “oxidative status” or “monosaccharides” or “sphingolipids” or “glycerophospholipids” or “acylcarnitines”. Additionally, more specific keywords were used: “aldosterone”, “androstenedione”, “androsterone”, “corticosterone”, “cortisol”, “cortisone”, “dehydroepiandrosterone”, “11-deoxycorticosterone”, “dihydrotestosterone”, “11-deoxycortisol”, “dehydro-epiandrosterone-sulfate”, “betaestradiol”, “estrone”, “eiocholanolone”, “17-alpha-hydroxyprogesterone”, “progesterone”, “testosterone”, “acetylornithine”, “asymmetric dimethylarginine”, “symmetric dimethylarginine”, “alpha-aminoadipic acid”, “carnosine”, “creatinine”, “histamine”, “kynurenine”, “methioninesulfoxide”, “nitrotyrosine”, “cis-4-hydroxyproline”, “trans-4-hydroxyproline”, “phenylethylamine”, “putrescine”, “sarcosine”, “serotonin”, “spermidine”, “spermine”, “taurine”, “dopamine”, “DOPA”, “lactate”, “3-phosphoglycerate”, “alpha-ketoglutaric acid”, “adenosine-3′,5′-cyclic monophosphate”, “arginine”, “aspartate”, “dihydroxyacetonephosphate”, “fumarate”, “glutamate”, “hexose”, “hexosephosphate”, “pentosephosphate”, “pyruvate”, “succinate”, “tetrosephosphate”, “hexoses”, “glutathione”, “glutathione-disulfide”, “cysteine”, “cystine”, “homocysteine”, and “homocystine”. Additional systematic reviews of the topic were included if they provided new insights and evidence. As shown in Fig. 1, 4722 of 4773 articles were excluded due to duplication, absence of full text or inappropriate contents. Letters and case reports were also excluded.
Promising metabolic biomarkers for prediction of all-cause mortality
Pathway and physiological role
Only few tissues contribute substantially to de novo steroid biosynthesis: primarily the adrenal glands, the gonads, and the placenta . All steroid hormones are derived from cholesterol. Cholesterol enters the cell via lipoprotein-binding and is stored in cytoplasmic vacuoles. After binding of adrenocorticotropic hormone (ACTH) to its receptor (melanocortin receptor type 2, MC2R) on adrenal cells, cholesterol is mobilized and thus available for steroid synthesis. Follicle-stimulating hormone (FSH) is critical in estradiol synthesis before and during ovulation and Luteinizing hormone (LH) for synthesis of progesterone. In the placenta, steroid biosynthesis is dependent on human chorionic gonadotropin (hCG) in early gestation .
One of the first measurable physiopathological reactions to infection is the activation of the hypothalamo-pituitary-adrenal (HPA) axis via stimulation of the central noradrenergic stress system by cytokines and other mediators that are released in response to inflammation [44–46]. Under healthy conditions, cortisol secretion is synchronized with dehydroepiandrosterone (DHEA) in response to the release of ACTH and corticotropin-releasing hormone (CRH), whereas in critically ill patients the circadian pattern of cortisol is lost  and DHEA and dehydroepiandrosterone-sulfate (DHEA-S) decrease . Although the physiological role of DHEA and DHEA-S is not completely understood, there are clear indications that they modulate the immune response and influence proinflammatory and anti-inflammatory cytokine release [48–52]. In severely ill pneumonia patients, an intra-adrenal shift from DHEA-S to cortisol production occurs, which might be a potentially life-saving process during critical illness and thus important for survival in CAP . Estradiol induces activation of macrophages and production of proinflammatory cytokines and chemokines from inflammatory cells [54–56], and testosterone has suppressive effects on immune responses, thereby inducing increased suceptibility to infection . In autoimmune diseases progesterone shows proinflammatory and anti-inflammatory effects .
Current research (Table 1)
Table 1 lists several studies reporting that increased cortisol (free and total) levels measured at initial hospital presentation are independent predictors of in-hospital and short-term all-cause mortality in hospitalized patients with mild to severe CAP [53, 59–62]. Interestingly, the predictive accuracy of free cortisol (FC) is equal to that of total cortisol (TC) in pneumonia, independent of serum albumin levels . The prognostic accuracy of cortisol in predicting mortality is equal to that of the PSI, but higher compared to routinely measured laboratory parameters such as CRP, PCT or leukocytes, which do not show significant differences (p > 0.05) [59–61]. Kolditz et al. observed that serum cortisol levels may noticeably improve the predictive power of the CURB-65 score alone as regards short-term mortality [60, 61]. Salluh et al. demonstrated that compared to baseline serum cortisol levels, which are proven independent mortality predictors, neither postcorticotropin cortisol nor Δ-cortisol has notable predictive power in severe CAP . A recent animal study of canines suffering from staphylococcus aureus pneumonia showed that ACTH stimulation induces a pronounced correlation between all-cause mortality and cortisol (free and total) levels and Δ-cortisol .
Conflicting results mark studies evaluating the role of serum DHEA as a mortality predictor. A prospective clinical trial conducted by Mueller et al. demonstrated that increased DHEA predicts 6-week mortality in CAP, whereas blood levels of DHEA-S as well as different ratios between cortisol and DHEA, cortisol and DHEA-S, and DHEA and DHEA-S shows no significant correlation with all-cause mortality . Contrary to these findings, Kolditz et al. found no difference in DHEA levels in non-survivors compared to survivors, whereas the lack of significance for the ratio between DHEA and DHEA-S as a mortality predictor accords with the results of Mueller et al. [53, 61]. Data on patients suffering from sepsis reveal a noticeable dissociation between cortisol and DHEA in non-survivors compared to survivors, and from this observation it can be inferred that an increased cortisol/DHEA ratio is a prognostic marker in sepsis . However, although the cortisol/DHEA ratio in clinical studies of CAP patients is not significant in the prediction of mortality, nevertheless, in non-survivors an increased cortisol/DHEA ratio occurs as a tendency . In elderly Swedish men, an inverse association between serum DHEA and DHEA-S is evident, whereas low serum DHEA and high DHEA-S levels are independent predictors of all-cause mortality . Furthermore Hsu et al. demonstrated a marked and independent association between low levels of plasma DHEA-S and higher mid-term all-cause mortality in men with chronic kidney disease (CKD) who were undergoing hemodialysis .
Table 1 depicts the strong association between increased serum estradiol and progesterone levels and 28-day mortality in patients suffering from pneumonia-related septic shock, whereas serum testosterone levels are not noticeably different between survivors and non-survivors after a 28-day follow-up . A prospective clinical study of elderly men who were free of cardiovascular disease at the time of blood sample collection, revealed a significant inverse association between dehydrotestosterone (DHT) and calculated free DHT levels with all-cause mortality during a follow-up period of 9 years, whereas total testosterone and calculated free testosterone showed no significant correlation with mortality . Contrary to these findings, Friedrich et al. and Grossmann et al. observed that low serum total testosterone levels in men with and without CKD significantly and independently predict all-cause mortality [69, 70], whereas another population-based clinical study of 40- to 70-year-old men  observed no significant association with either total or free testosterone, or with DHT in all-cause mortality in multivariate-adjusted analysis.
In postmenopausal women low estrone levels independently predict long-term all-cause mortality .
I. L-arginine metabolites: Asymmetric dimethylarginine and symmetric dimethylarginine
Pathway and physiological role
Endothelial nitric oxide synthases (NOS) synthesize nitric oxide (NO) from L-arginine (Arg). NO is responsible for vasodilatation and acts as a neurotransmitter with several functions, including memory formation . NO promotes relaxation of airway smooth muscle in the respiratory system, but NO deficiency results in hyperreactivity of the airway . Asymmetric dimethylarginine (ADMA) and its isomer symmetric dimethylarginine (SDMA) are endogenous compounds of methylated protein turnover. ADMA—but not SDMA—is a competitive inhibitor of NOS and thus indirectly of NO . One study shows that ADMA is present in the sputum of COPD patients .
Current research (Table 2)
A large community-based study of middle-aged participants revealed a positive association between ADMA levels and long-term mortality, whereas the Arg/ADMA ratio was inversely associated with death rate . In people >65 years, ADMA is the strongest predictor of all-cause mortality, while some traditional risk factors—e.g., body mass index, systolic and diastolic blood pressure, male sex or triglycerides—lose their predictive power in this age group . Additionally, elevated ADMA and SDMA serum levels correlate noticeably with higher all-cause mortality in patients with stable CHD  and in critically ill patients [80, 81]. Contrary to these findings, another study—after adjustment for NT-proBNP, hsCRP, troponin T and cardiorenal indices—reveaed that SDMA, but not ADMA, is an independent predictor of all-cause mortality .
Pathway and physiological role
Tryptophan (Trp) is an essential amino acid. Degradation of Trp to its toxic metabolite kynurenine (Kyn) is catalyzed by the enzyme indoleamine 2,3-dioxygenase (IDO), which is expressed in a variety of cells; e.g., monocyte-derived macrophages and dentritic cells . Moreover, IDO induces inhibition of T-cell proliferation  and its activity is measured by the kynurenine-to-tryptohan ratio (Kyn/Trp ratio) [85–87].
Current research (Table 2)
Subjects with CAP  and sepsis  show significantly higher Kyn levels and lower Trp levels compared to controls. As a result, the Kyn/Trp ratio, which represents the IDO activity, is elevated in CAP and sepsis [85, 86]. Increased severity of CAP (defined by PSI and CURB-65 score)  and of sepsis  are associated with higher Kyn levels, higher Kyn/Trp ratios and lower Trp levels. In patients with CAP  or bacteremia , short-term non-survivors have higher Kyn/Trp ratios than do survivors, whereas the sepsis group manifests no marked difference in Kyn/Trp ratio between non-survivors and survivors in the short-term .
Pathway and physiological role
Homeostatic balance is usually maintained between the formation of reactive oxygen species (ROS) and its removal by endogenous antioxidants. Oxidative stress arises from an imbalance towards ROS production . Peroxynitrite (ONOO−) is a potent oxidant of this ROS group and catalyzes nitration of the non-essential amino acid tyrosine (Tyr) to the non-proteinogenic amino acid 3-nitrotyrosine (3-NT) . Accordingly, nitrotyrosine is a characteristic marker of oxidative stress (e.g., inflammation) .
Protein-associated nitrotyrosine is lower in smokers than in non-smokers, evidence consistent with a lower production of endothelial NO in cigarette smokers. In contrast, smokers with COPD show higher average nitrotyrosine levels in plasma proteins compared with smokers without COPD. Therefore, it seems that chronic inflammatory processes in COPD patients increase the nitration of Tyr .
Current research (Table 2)
As shown in Table 2, subjects with hospital-acquired acute kidney injury (AKI) have higher 3-nitrotyrosin/tyrosine ratios (3-NT/Tyr) than do critically ill subjects without AKI and healthy controls. In the AKI group, the 3-NT/Tyr ratio is positively associated with 90-day mortality independent of the severity of illness .
Trimethylamine-N-oxide, betaine, choline
Pathway and physiological role
Synthesis of phospholipids to build cell membranes, acetylcholine for neurotransmission just as the methyl group metabolism depend on dietary phosphatidylcholine (PC)/choline intake . The liver and kidney can both oxidize choline to betaine. Betaine is an important metabolite in methyl group metabolism; it functions as a methyl group donor to form methionine [94, 95]. Eggs, red meat, beef and chicken liver, wheat germ, bacon, dried soy beans and pork contain the highest concentration of total choline. Betaine levels are high in wheat bread, wheat bran, wheat germ, spinach and shrimp . Intestinal microbes (gut microflora) transform choline and other quaternary ammonium compounds (e.g., betaine) to the gas trimethylamine (TMA) . This gas is reabsorbed efficiently into the circulation and then into human liver. Hepatic flavin-containing monooxygenases (FMOs) rapidly oxidize TMA to trimethylamine-N-oxide (TMAO) . Thus TMA is not produced via intermediary metabolism; rather, it depends on intestinal microbial breakdown of choline and other precursors. Thus for the production of TMA and its oxidation product TMAO, intact and functional intestinal microflora are essential [97, 99].
Current research (Table 3)
Several animal studies show the effects of elevated TMAO levels. An increase in the concentration of plasma TMAO was observed in mice, which were fed with either choline or TMAO [99, 100]. After 16 weeks of feeding there was a marked increase in tubulointerstitial fibrosis and serum cystatin C . A significant positive correlation between plasma levels of TMAO and atherosclerotic plaque size after 20 weeks of feeding in both male and female mice was observed. Furthermore, macrophages from mice supplemented with either choline, betaine or TMAO showed augmented lipid-loaded macrophages and higher levels of the macrophage scavenger receptors CD36 and SR-A1. These receptors implicate atherosclerosis. In a mouse model, application of broad-spectrum antibiotics for 3 weeks suppressed dietary choline-induced formation of macrophage foam cells and choline-mediated enhancement in atherosclerosis .
In humans (3), higher plasma NT-proBNP [101, 102] and advanced left ventricular diastolic dysfunction are associated with elevated plasma betaine, choline and TMAO. TMAO levels are markedly higher in patients with heart failure NYHA III/IV or diabetes mellitus. Baseline plasma levels of TMAO have marked prognostic value for major adverse cardiovascular events in low-risk subgroups after adjustments for age and cardiorenal indices [102, 103]. Since cardiovascular disease (CVD) remains the major cause of deaths , these findings might be predictive of poor outcome. In addition, elevated TMAO levels are predictive of 5-year mortality risk in subjects with heart failure after adjustment for cardiovascular risk factors and renal function .
In healthy adults a dietary PC challenge raises TMAO level. In six human participants this elevation was suppressed with oral broad-spectrum antibiotics .
A high correlation is evident between plasma and urine levels of TMAO, which indicates an effective urinary clearance of TMAO . Median TMAO blood levels in subjects with CKD stage 3 or beyond are markedly higher than in non-CKD subjects. Moreover, there is a modest correlation between elevated TMAO with low estimated glomerular filtration rate (eGFR) and high cystatin C. After adjustment for traditional cardiovascular risk factors an increased all-cause mortality rate at 5 years for CKD subjects with a higher TMAO level is evident. In subjects with preserved eGFR (>60 mL/min per 1.73 m2) higher TMAO levels are associated with higher 5-year mortality, particularly in patients who have concomitant high cystatin C levels .
Intermediate energy metabolism
Pathway and physiological role
Glycolysis produces the metabolite pyruvate. Lactate dehydrogenase (LDH) converts pyruvate to lactic acid under anaerobic conditions. Lactate acid dissociates spontaneously to lactate and H+ in aqueous solutions. Thus lactate is the end product of anaerobic glucose metabolism in erythrocytes, perivenous hepatocytes, skeletal myocytes and skin cells. A normal plasma lactate concentration is 0.3-1.3 mmol/L and the liver removes 70 % of the lactate. An imbalance between systemic oxygen demand and oxygen availability (e.g., hypoperfusion in patients with sepsis) heightens anaerobic metabolism and results in lactic acidosis [105, 106].
Current research (Table 4)
In children with pneumonia, relative risk for in-hospital mortality is higher if the lactate level is above 2 mmol/L . In adults with pneumonia, lactate level is the better predictor of 28-day mortality than the CURB-65 score, whereas a combination of CURB-65 with lactate level improves the predictive value of CURB-65 alone (Table 4) .
Lactate >3.5 mmol/L in combination with a PaO2/FiO2 (PF) ratio <170 is associated with a higher 28-day mortality rate; accordingly, a combination of serum lactate and the PF ratio may be a useful predictor of mortality in patients with sepsis, including pneumonia . Metabolic profiling of plasma from 90 critically ill intensive care unit (ICU) patients revealed significantly higher lactate levels in non-survivors compared with survivors in 28-day mortality .
Pathway and physiological role
Monosaccharides are the simplest form of sugar and therefore the most basic units of carbohydrates; they are important as an energy resource. The most important monosaccharides in human metabolism are the three aldohexoses (D-glucose, D-mannose, and D-galactose), and D-fructose, a sugar monomer of the ketohexose series of carbohydrates .
Current research (Table 5)
In patients with CAP (Table 5) , hypoglycemia  and hyperglycemia are associated with a higher rate of in-hospital mortality [112, 113] and in-hospital complications . Furthermore, hyperglycemia is a predictor of death at 28 and 90 days after admission to hospital in patients with CAP and no pre-existing diabetes .
Pathway and physiological role
Reactive oxygen species (ROS) and reactive nitrogen species (RNS) are important in regulating the proliferation of cells and their survival. However, a sudden and prolonged surge of ROS and RNS may contribute to cell death. The redox homeostasis of cells, which maintains a balance between the generation and elimination of ROS and RNS ensures that endogenous and exogenous stimuli are modulated. Altered redox homeostasis leads to oxidative stress, which may cause aberrant cell death and the development of disease . Glutathione (gamma-glutamyl-cysteinyl-glycine, GSH) is the predominant antioxidant non-protein cysteine-containing thiol, which is found in all animal cells. It is important in maintaining the status of cellular redox, which is determined by the ratio of the concentration of oxidizing equivalents to reducing equivalents , and it is the principal intracellular defense against oxidative stress. GSH has two redox forms: reduced GSH and glutathione disulfide (GSSG, the oxidized form) . Cells can excrete GSSG or restore it to GSH through the action of GSH reductase. De novo synthesis of GSH from its amino-acid constituents—a process that involves two enzymatic steps catalyzed by glutamate cysteine ligase and GSH synthetase—  is essential for the adaptive elevation of GSH during oxidative stress . The rate-limiting step in the de novo synthesis of GSH occurs at the cellular level of the amino acid cysteine . Additionally, reduction of cystine to cysteine is an important mechanism for intracellular GSH elevation in vivo in lungs . During oxidative stress and inflammation, synthesis of GSH is upregulated, possibly providing a protective or adaptive response to subsequent oxidative and inflammatory stress. An imbalance of antioxidant and proinflammatory genes can lead to chronic inflammation .
Homocysteine is built from the breakdown of the essential amino acid methionine and can subsequently be converted to cystathionine with vitamin B6 and further to cysteine. Conversely, vitamin B12 promotes remethylation of homocysteine to methionine [121, 122]. The latter reaction is catalyzed by the enzyme methionine synthase, requiring 5-methyltetrahydrofolate, the main circulating form of folate, and vitamin B12 in its co-factor form methylcobalamin .
Current research (Table 6)
Table 6 outlines a clinical study that ascertained the status of glutathione—reflected by the reduced ratio of glutathione (GSH) to total glutathione in whole blood—as an independent mid-term predictor of all-cause mortality in post-ICU patients, whereas the total concentration of glutathione as well as the concentration of GSH alone revealed no association with 6-month mortality . Although total glutathione and GSH concentrations in ICU patients have been observed as low, the quartile with the highest redox ratio of glutathione (GSH/total glutathione) carries the highest post-ICU all-cause mortality risk . Lower levels of glutathione-S-bimane (GSB)—that is, intracellular GSH measured by fluorescence-activated cell sorter (FACS)—in CD4 T cells are prominent long-term mortality predictors in HIV-infected individuals, independent of CD4 T cell count .
Several clinical studies have demonstrated that elevated levels of plasma homocysteine independently predict long-term all-cause mortality in the elderly [124–127] as well as in younger adults [128, 129]. In contrast, in patients after ischemic stroke a marked association is evident between high plasma homocysteine and overall mortality only after exclusion of patients with dissection . Another study showed a correlation between higher homocysteine levels and increased long-term mortality in the subgroup of patients with malnutrition and inflammation . Additionally, elevated plasma homocysteine levels are discernibly related to a higher death rate only in older women . Besides their relation to all-cause mortality, high homocysteine concentrations are independently associated with cardiovascular mortality .
Pathway and physiological role
Glycerophospholipids are glycerol-based phospholipids that form the bilayer in biological membranes. Their basic structure is composed of glycerol, to which a phosphoric acid and two fatty acids are attached as esters. An additional alcohol group (e.g., serine, choline, ethanolamine or inositol) attached to the phosphate allows the formation of distinct phosphoglycerides. The five classes of glycerophospholipids are phosphatidylcholine (PC, lecithin), phosphatidylethanolamine (PE), phosphatidylserine (PS), phosphatidylinositol (PI) and diphosphatidylgylcerol (cardiolipin) .
Current research (Table 7)
In lipid profiling of patients undergoing coronary angiography, 19 PC and 3 lysophosphatidylcholine (lysoPC) species reveal a noticeable association with mortality due to total and coronary artery disease. Ten of 19 PC and all 3 analyzed lysoPC species are inversely associated with mortality, whereas PC 32:0 reveals the strongest positive correlation with mortality . Four lysoPC species—C16:0, C18:0, C18:1, and C18:2—account for over 90 % of total plasma lysoPC concentration. The levels of these main lysoPC species as well as total lysoPC concentrations are markedly reduced in sepsis, including pulmonary infections, compared to healthy controls (Table 7). Moreover, 30-day non-survivors show higher ratios of lysoPC/PC compared with survivors .
Pathway and physiological role
Sphingolipids are essential components of cell membranes, and in neural tissue they are important in signal transduction and cell recognition. Fundamental building blocks of sphingolipids are long-chain bases (sphingoid bases). Their amine group is linked to an acyl group (e.g., fatty acid) and the backbone of the sphingoid base is linked with phosphate to an alcohol group (serine, ethanolamine or choline). The 3 principal forms of sphingolipids are ceramide and its derivatives sphingomyelin (SM) and glycosphingolipids .
Current research (Table 7)
Elevated plasma SM levels are an independent risk factor for CHD and an outcome predictor in patients with acute coronary syndrome [135, 136]. In lipid profiling of patients undergoing coronary angiography, 9 SM species are significantly associated with total and CHD long-term mortality (Table 7). Of 9 SM species, 5 showed an inverse association and 4 (specifically SM 16:0, 16:1, 24:1, and 24:2) displayed a positive association with total and cardiovascular mortality .
Pathway and physiological role
Carnitine (3-Hydroxy-4-N-trimethylammoniobutanoate) is biosynthesized in the liver and kidneys from the amino acids lysine and methionine. Nutrition is an important, but not essential, source of carnitine. The highest concentrations of carnitine are found in red meat, but carnitine is also found in other foods such as nuts, seeds, legumes, vegetables, fruits and cereals. Fatty acid oxidation and thus fatty acid energy metabolism occur in the cellular mitochondria. In the cytosol, free fatty acids are attached with a thioester bond to coenzyme A (CoA). Carnitine transports long-chain acyl groups of fatty acids from the cellular cytosol through the mitochondrial membrane. On the outer mitochondrial membrane, carnitine acyltransferase l transfers acyl-CoA to the hydroxyl group of carnitine, resulting in acylcarnitine. The enzyme carnitine-acylcarnitine translocase catalyzes the transport of acylcarnitine to the inner mitochondrial membrane where carnitine acyltransferase II re-converts acylcarnitine to acyl-CoA .
Current research (Table8 )
Metabolic profiling of 165 polar metabolites was performed in hemodialysis patients. Individuals who died of a cardiovascular cause within 1 year of initiating hemodialysis revealed markedly higher concentrations of the 4 long-chain acylcarnitines oleoylcarnitine, linoleylcarnitine, palmitoylcarnitine, and stearoylcarnitine compared with survivors who had undergone hemodialysis for 1 year. Of these metabolites, oleoylcarnitine showed the strongest association with cardiovascular mortality after multivariable adjustment (Table 8) .
Since many uncertainties remain in predicting all-cause mortality in patients hospitalized for CAP or for exacerbated COPD, additional prospective and retrospective observational studies are needed to ascertain other potential contributors to all-cause mortality in order to improve the prediction of initial high risk. Metabolomic analysis using MS may facilitate identification of outcome-specific metabolite signatures that could potentially generate new metabolic biomarkers of various organic systems as all-cause mortality predictors in CAP and in exacerbated COPD. Improvement in early and accurate identification of high-risk patients can help optimize short- and long-term management strategies in LRTI and as a result, potentially improve survival, leading to a more cost-effective allocation of medical resources. In addition, deeper knowledge of metabolic interactions in LRTI may provide new targets for future individual therapy and also be beneficial in predicting responses to therapy.
Acute kidney injury
- AUC (or AUROC):
Area under the receiver operating characteristic curve
Body mass index, airflow obstruction, dyspnea and exercise capacity index
Coronary heart disease
Chronic kidney disease
Chronic obstructive pulmonary disease
New-onset confusion, urea >7 mmol/L, respiratory rate ≥30 breaths/min, systolic or diastolic blood pressure <90 mmHg or ≤60 mmHg, respectively, age ≥65 years (pneumonia/LRTI risk scoring system)
Estimated glomerular filtration rate
Fluorescence-activated cell sorter
Intensive care unit
Lower respiratory tract infection
Nitric oxide synthases
Pro-B-type natriuretic peptide
Pneumonia severity index
Reactive nitrogen species
Receiver operating characteristics
Reactive oxygen species
Oliver SG, Winson MK, Kell DB, Baganz F. Systematic functional analysis of the yeast genome. Trends Biotechnol. 1998;16(9):373–8.
Fiehn O. Combining genomics, metabolome analysis, and biochemical modelling to understand metabolic networks. Comp Funct Genomics. 2001;2(3):155–68.
Wheelock CE, Goss VM, Balgoma D, Nicholas B, Brandsma J, Skipp PJ, et al. Application of 'omics technologies to biomarker discovery in inflammatory lung diseases. Eur Respir J. 2013;42(3):802–25.
Kaddurah-Daouk R, Kristal BS, Weinshilboum RM. Metabolomics: a global biochemical approach to drug response and disease. Annu Rev Pharmacol Toxicol. 2008;48:653–83.
Konig S. Urine molecular profiling distinguishes health and disease: new methods in diagnostics? Focus on UPLC-MS. Expert Rev Mol Diagn. 2011;11(4):383–91.
Tenori L, Oakman C, Claudino WM, Bernini P, Cappadona S, Nepi S, et al. Exploration of serum metabolomic profiles and outcomes in women with metastatic breast cancer: a pilot study. Mol Oncol. 2012;6(4):437–44.
Zhang A, Sun H, Dou S, Sun W, Wu X, Wang P, et al. Metabolomics study on the hepatoprotective effect of scoparone using ultra-performance liquid chromatography/electrospray ionization quadruple time-of-flight mass spectrometry. Analyst. 2013;138(1):353–61.
Schuetz P, Aujesky D, Muller C, Muller B. Biomarker-guided personalised emergency medicine for all - hope for another hype? Swiss Med Wkly. 2015;145:w14079.
Weckwerth W. Metabolomics in systems biology. Annu Rev Plant Biol. 2003;54:669–89.
Kutz A, Briel M, Christ-Crain M, Stolz D, Bouadma L, Wolff M, et al. Prognostic value of procalcitonin in respiratory tract infections across clinical settings. Crit Care. 2015;19(1):74.
Schuetz P, Mueller B. The role of immune and metabolic biomarkers for improved management of sepsis patients. Expert Rev Clin Immunol. 2014;10(9):1255–62.
Schuetz P, Mueller B. Biomarker-guided de-escalation of empirical therapy is associated with lower risk for adverse outcomes. Intensive Care Med. 2014;40(1):141.
Rast A, Mueller B, Schuetz P. Clinical scores and blood biomarkers for early risk assessment of patients presenting to the emergency department. OA Emergency Medicine. 2014;1(1):2.
Albrich WC, Ruegger K, Dusemund F, Schuetz P, Arici B, Litke A, et al. Biomarker-enhanced triage in respiratory infections: a proof-of-concept feasibility trial. Eur Respir J. 2013;42(4):1064–75.
Schuetz P, Wolbers M, Christ-Crain M, Thomann R, Falconnier C, Widmer I, et al. Prohormones for prediction of adverse medical outcome in community-acquired pneumonia and lower respiratory tract infections. Crit Care. 2010;14(3):R106.
Schuetz P, Raad I, Amin DN. Using procalcitonin-guided algorithms to improve antimicrobial therapy in ICU patients with respiratory infections and sepsis. Curr Opin Crit Care. 2013;19(5):453–60.
Schuetz P, Litke A, Albrich WC, Mueller B. Blood biomarkers for personalized treatment and patient management decisions in community-acquired pneumonia. Curr Opin Infect Dis. 2013;26(2):159–67.
Schuetz P, Hausfater P, Amin D, Haubitz S, Fassler L, Grolimund E, et al. Optimizing triage and hospitalization in adult general medical emergency patients: the triage project. BMC Emerg Med. 2013;13:12.
Kung HC, Hoyert DL, Xu J, Murphy SL. Deaths: final data for 2005. Natl Vital Stat Rep. 2008;56(10):1–120.
Brown PD, Lerner SA. Community-acquired pneumonia. Lancet. 1998;352(9136):1295–302.
File TM. Community-acquired pneumonia. Lancet. 2003;362(9400):1991–2001.
Schuetz P, Albrich WC, Suter I, Hug BL, Christ-Crain M, Holler T, et al. Quality of care delivered by fee-for-service and DRG hospitals in Switzerland in patients with community-acquired pneumonia. Swiss Med Wkly. 2011;141:w13228.
Menendez R, Torres A, Zalacain R, Aspa J, Martin Villasclaras JJ, Borderias L, et al. Risk factors of treatment failure in community acquired pneumonia: implications for disease outcome. Thorax. 2004;59(11):960–5.
Almirall J, Bolibar I, Vidal J, Sauca G, Coll P, Niklasson B, et al. Epidemiology of community-acquired pneumonia in adults: a population-based study. Eur Respir J. 2000;15(4):757–63.
Guertler C, Wirz B, Christ-Crain M, Zimmerli W, Mueller B, Schuetz P. Inflammatory responses predict long-term mortality risk in community-acquired pneumonia. Eur Respir J. 2011;37(6):1439–46.
Schuetz P, Suter-Widmer I, Chaudri A, Christ-Crain M, Zimmerli W, Mueller B, et al. Prognostic value of procalcitonin in community-acquired pneumonia. Eur Respir J. 2011;37(2):384–92.
Suter-Widmer I, Christ-Crain M, Zimmerli W, Albrich W, Mueller B, Schuetz P, et al. Predictors for length of hospital stay in patients with community-acquired pneumonia: results from a Swiss multicenter study. BMC Pulm Med. 2012;12:21.
Alan M, Grolimund E, Kutz A, Christ-Crain M, Thomann R, Falconnier C, et al. Clinical risk scores and blood biomarkers as predictors of long-term outcome in patients with community-acquired pneumonia: a 6-year prospective follow-up study. J Intern Med. 2014;278(2):174–84.
Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997;336(4):243–50.
Niederman MS, Mandell LA, Anzueto A, Bass JB, Broughton WA, Campbell GD, et al. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med. 2001;163(7):1730–54.
Schuetz P, Marlowe RJ, Mueller B. The prognostic blood biomarker proadrenomedullin for outcome prediction in patients with chronic obstructive pulmonary disease (COPD): a qualitative clinical review. Clin Chem Lab Med. 2015;53(4):521–39.
Grolimund E, Kutz A, Marlowe RJ, Vogeli A, Alan M, Christ-Crain M, et al. Long-term Prognosis in COPD Exacerbation: Role of Biomarkers, Clinical Variables and Exacerbation Type. COPD. 2014.
Schuetz P, Christ-Crain M, Morgenthaler NG, Struck J, Bergmann A, Muller B. Circulating precursor levels of endothelin-1 and adrenomedullin, two endothelium-derived, counteracting substances, in sepsis. Endothelium. 2007;14(6):345–51.
Huang DT, Weissfeld LA, Kellum JA, Yealy DM, Kong L, Martino M, et al. Risk prediction with procalcitonin and clinical rules in community-acquired pneumonia. Ann Emerg Med. 2008;52(1):48–58. e2.
Jensen JU, Heslet L, Jensen TH, Espersen K, Steffensen P, Tvede M. Procalcitonin increase in early identification of critically ill patients at high risk of mortality. Crit Care Med. 2006;34(10):2596–602.
Haeuptle J, Zaborsky R, Fiumefreddo R, Trampuz A, Steffen I, Frei R, et al. Prognostic value of procalcitonin in Legionella pneumonia. Eur J Clin Microbiol Infect Dis. 2009;28(1):55–60.
Kruger S, Ewig S, Marre R, Papassotiriou J, Richter K, von Baum H, et al. Procalcitonin predicts patients at low risk of death from community-acquired pneumonia across all CRB-65 classes. Eur Respir J. 2008;31(2):349–55.
Restrepo MI, Faverio P, Anzueto A. Long-term prognosis in community-acquired pneumonia. Curr Opin Infect Dis. 2013;26(2):151–8.
Kellum JA, Kong L, Fink MP, Weissfeld LA, Yealy DM, Pinsky MR, et al. Understanding the inflammatory cytokine response in pneumonia and sepsis: results of the Genetic and Inflammatory Markers of Sepsis (GenIMS) Study. Arch Intern Med. 2007;167(15):1655–63.
Stolz D, Kostikas K, Blasi F, Boersma W, Milenkovic B, Lacoma A, et al. Adrenomedullin refines mortality prediction by the BODE index in COPD: the "BODE-A" index. Eur Respir J. 2014;43(2):397–408.
Zuur-Telgen MC, Brusse-Keizer MG, Vandervalk PD, van der Palen J, Kerstjens HA, Hendrix MG. Stable state MR-proadrenomedullin level is a strong predictor for mortality in COPD patients. Chest. 2013. doi:10.1378/chest.13-1063.
Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, Mendez RA, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med. 2004;350(10):1005–12.
Ghayee HK, Auchus RJ. Basic concepts and recent developments in human steroid hormone biosynthesis. Rev Endocr Metab Disord. 2007;8(4):289–300.
Chrousos GP. The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N Engl J Med. 1995;332(20):1351–62.
Nylen ES, Muller B. Endocrine changes in critical illness. J Intensive Care Med. 2004;19(2):67–82.
Muller B. Endocrine aspects of critical illness. Ann Endocrinol (Paris). 2007;68(4):290–8.
Van den Berghe GH. Acute and prolonged critical illness are two distinct neuroendocrine paradigms. Verh K Acad Geneeskd Belg. 1998;60(6):487–518. discussion -20.
Vermes I, Beishuizen A. The hypothalamic-pituitary-adrenal response to critical illness. Best Pract Res Clin Endocrinol Metab. 2001;15(4):495–511.
Blum CA, Mueller C, Schuetz P, Fluri F, Trummler M, Mueller B, et al. Prognostic value of dehydroepiandrosterone-sulfate and other parameters of adrenal function in acute ischemic stroke. PLoS One. 2013;8(5):e63224.
Oberbeck R, Kobbe P. Dehydroepiandrosterone (DHEA): a steroid with multiple effects. Is there any possible option in the treatment of critical illness? Curr Med Chem. 2010;17(11):1039–47.
Oberbeck R, Dahlweid M, Koch R, van Griensven M, Emmendorfer A, Tscherne H, et al. Dehydroepiandrosterone decreases mortality rate and improves cellular immune function during polymicrobial sepsis. Crit Care Med. 2001;29(2):380–4.
Schmitz D, Kobbe P, Wegner A, Hammes F, Oberbeck R. Dehydroepiandrosterone during sepsis: does the timing of administration influence the effectiveness. J Surg Res. 2010;163(2):e73–7.
Mueller C, Blum CA, Trummler M, Stolz D, Bingisser R, Mueller C, et al. Association of adrenal function and disease severity in community-acquired pneumonia. PLoS One. 2014;9(6):e99518.
Liarte S, Chaves-Pozo E, Abellan E, Meseguer J, Mulero V, Garcia-Ayala A. 17beta-Estradiol regulates gilthead seabream professional phagocyte responses through macrophage activation. Dev Comp Immunol. 2011;35(1):19–27.
Bengtsson AK, Ryan EJ, Giordano D, Magaletti DM, Clark EA. 17beta-estradiol (E2) modulates cytokine and chemokine expression in human monocyte-derived dendritic cells. Blood. 2004;104(5):1404–10.
Asai K, Hiki N, Mimura Y, Ogawa T, Unou K, Kaminishi M. Gender differences in cytokine secretion by human peripheral blood mononuclear cells: role of estrogen in modulating LPS-induced cytokine secretion in an ex vivo septic model. Shock. 2001;16(5):340–3.
Rahman F, Christian HC. Non-classical actions of testosterone: an update. Trends Endocrinol Metab. 2007;18(10):371–8.
Hughes GC. Progesterone and autoimmune disease. Autoimmun Rev. 2012;11(6-7):A502–14.
Christ-Crain M, Stolz D, Jutla S, Couppis O, Muller C, Bingisser R, et al. Free and total cortisol levels as predictors of severity and outcome in community-acquired pneumonia. Am J Respir Crit Care Med. 2007;176(9):913–20.
Kolditz M, Hoffken G, Martus P, Rohde G, Schutte H, Bals R, et al. Serum cortisol predicts death and critical disease independently of CRB-65 score in community-acquired pneumonia: a prospective observational cohort study. BMC Infect Dis. 2012;12:90.
Kolditz M, Halank M, Schulte-Hubbert B, Hoffken G. Adrenal function is related to prognosis in moderate community-acquired pneumonia. Eur Respir J. 2010;36(3):615–21.
Salluh JI, Bozza FA, Soares M, Verdeal JC, Castro-Faria-Neto HC, Lapa ESJR, et al. Adrenal response in severe community-acquired pneumonia: impact on outcomes and disease severity. Chest. 2008;134(5):947–54.
Cortes-Puch I, Hicks CW, Sun J, Solomon SB, Eichacker PQ, Sweeney DA, et al. Hypothalamic-pituitary-adrenal axis in lethal canine Staphylococcus aureus pneumonia. Am J Physiol Endocrinol Metab. 2014;307(11):E994–E1008.
Arlt W, Hammer F, Sanning P, Butcher SK, Lord JM, Allolio B, et al. Dissociation of serum dehydroepiandrosterone and dehydroepiandrosterone sulfate in septic shock. J Clin Endocrinol Metab. 2006;91(7):2548–54.
Ohlsson C, Labrie F, Barrett-Connor E, Karlsson MK, Ljunggren O, Vandenput L, et al. Low serum levels of dehydroepiandrosterone sulfate predict all-cause and cardiovascular mortality in elderly Swedish men. J Clin Endocrinol Metab. 2010;95(9):4406–14.
Hsu HJ, Yen CH, Chen CK, Hsu KH, Hsiao CC, Lee CC, et al. Low plasma DHEA-S increases mortality risk among male hemodialysis patients. Exp Gerontol. 2012;47(12):950–7.
Feng JY, Liu KT, Abraham E, Chen CY, Tsai PY, Chen YC, et al. Serum estradiol levels predict survival and acute kidney injury in patients with septic shock--a prospective study. PLoS One. 2014;9(6):e97967.
Shores MM, Biggs ML, Arnold AM, Smith NL, Longstreth Jr WT, Kizer JR, et al. Testosterone, dihydrotestosterone, and incident cardiovascular disease and mortality in the cardiovascular health study. J Clin Endocrinol Metab. 2014;99(6):2061–8.
Friedrich N, Schneider HJ, Haring R, Nauck M, Volzke H, Kroemer HK, et al. Improved prediction of all-cause mortality by a combination of serum total testosterone and insulin-like growth factor I in adult men. Steroids. 2012;77(1-2):52–8.
Grossmann M, Hoermann R, Ng Tang Fui M, Zajac JD, Ierino FL, Roberts MA. Sex steroids levels in chronic kidney disease and kidney transplant recipients: associations with disease severity and prediction of mortality. Clin Endocrinol (Oxf). 2014;82(5):767–75.
Araujo AB, Kupelian V, Page ST, Handelsman DJ, Bremner WJ, McKinlay JB. Sex steroids and all-cause and cause-specific mortality in men. Arch Intern Med. 2007;167(12):1252–60.
de Padua MA, Silva TC, Takada JY, Avakian SD, Strunz CM, Machado Cesar LA, et al. Long-term prospective study of the influence of estrone levels on events in postmenopausal women with or at high risk for coronary artery disease. Scientific World Journal. 2012;2012:363595.
Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med. 1993;329(27):2002–12.
Scott JA, North ML, Rafii M, Huang H, Pencharz P, Subbarao P, et al. Asymmetric dimethylarginine is increased in asthma. Am J Respir Crit Care Med. 2011;184(7):779–85.
Schwedhelm E, Boger RH. The role of asymmetric and symmetric dimethylarginines in renal disease. Nat Rev Nephrol. 2011;7(5):275–85.
Scott JA, Duongh M, Young AW, Subbarao P, Gauvreau GM, Grasemann H. Asymmetric dimethylarginine in chronic obstructive pulmonary disease (ADMA in COPD). Int J Mol Sci. 2014;15(4):6062–71.
Boger RH, Sullivan LM, Schwedhelm E, Wang TJ, Maas R, Benjamin EJ, et al. Plasma asymmetric dimethylarginine and incidence of cardiovascular disease and death in the community. Circulation. 2009;119(12):1592–600.
Pizzarelli F, Maas R, Dattolo P, Tripepi G, Michelassi S, D'Arrigo G, et al. Asymmetric dimethylarginine predicts survival in the elderly. Age (Dordr). 2013;35(6):2465–75.
Siegerink B, Maas R, Vossen CY, Schwedhelm E, Koenig W, Boger R, et al. Asymmetric and symmetric dimethylarginine and risk of secondary cardiovascular disease events and mortality in patients with stable coronary heart disease: the KAROLA follow-up study. Clin Res Cardiol. 2013;102(3):193–202.
Koch A, Weiskirchen R, Kunze J, Duckers H, Bruensing J, Buendgens L, et al. Elevated asymmetric dimethylarginine levels predict short- and long-term mortality risk in critically ill patients. J Crit Care. 2013;28(6):947–53.
Koch A, Weiskirchen R, Bruensing J, Duckers H, Buendgens L, Kunze J, et al. Regulation and prognostic relevance of symmetric dimethylarginine serum concentrations in critical illness and sepsis. Mediators Inflamm. 2013;2013:413826.
Gore MO, Luneburg N, Schwedhelm E, Ayers CR, Anderssohn M, Khera A, et al. Symmetrical dimethylarginine predicts mortality in the general population: observations from the Dallas heart study. Arterioscler Thromb Vasc Biol. 2013;33(11):2682–8.
Mellor AL, Munn DH. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol. 2004;4(10):762–74.
Hwu P, Du MX, Lapointe R, Do M, Taylor MW, Young HA. Indoleamine 2,3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation. J Immunol. 2000;164(7):3596–9.
Suzuki Y, Suda T, Yokomura K, Suzuki M, Fujie M, Furuhashi K, et al. Serum activity of indoleamine 2,3-dioxygenase predicts prognosis of community-acquired pneumonia. J Infect. 2011;63(3):215–22.
Darcy CJ, Davis JS, Woodberry T, McNeil YR, Stephens DP, Yeo TW, et al. An observational cohort study of the kynurenine to tryptophan ratio in sepsis: association with impaired immune and microvascular function. PLoS One. 2011;6(6):e21185.
Huttunen R, Syrjanen J, Aittoniemi J, Oja SS, Raitala A, Laine J, et al. High activity of indoleamine 2,3 dioxygenase enzyme predicts disease severity and case fatality in bacteremic patients. Shock. 2010;33(2):149–54.
Macdonald J, Galley HF, Webster NR. Oxidative stress and gene expression in sepsis. Br J Anaesth. 2003;90(2):221–32.
Beckman JS, Koppenol WH. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am J Physiol. 1996;271(5 Pt 1):C1424–37.
Pacher P, Beckman JS, Liaudet L. Nitric oxide and peroxynitrite in health and disease. Physiol Rev. 2007;87(1):315–424.
Jin H, Webb-Robertson BJ, Peterson ES, Tan R, Bigelow DJ, Scholand MB, et al. Smoking, COPD, and 3-nitrotyrosine levels of plasma proteins. Environ Health Perspect. 2011;119(9):1314–20.
Qian J, You H, Zhu Q, Ma S, Zhou Y, Zheng Y, et al. Nitrotyrosine level was associated with mortality in patients with acute kidney injury. PLoS One. 2013;8(11):e79962.
Zeisel SH, Blusztajn JK. Choline and human nutrition. Annu Rev Nutr. 1994;14:269–96.
Millian NS, Garrow TA. Human betaine-homocysteine methyltransferase is a zinc metalloenzyme. Arch Biochem Biophys. 1998;356(1):93–8.
Finkelstein JD, Harris BJ, Kyle WE. Methionine metabolism in mammals: kinetic study of betaine-homocysteine methyltransferase. Arch Biochem Biophys. 1972;153(1):320–4.
Zeisel SH, Mar MH, Howe JC, Holden JM. Concentrations of choline-containing compounds and betaine in common foods. J Nutr. 2003;133(5):1302–7.
Al-Waiz M, Mikov M, Mitchell SC, Smith RL. The exogenous origin of trimethylamine in the mouse. Metabolism. 1992;41(2):135–6.
Lang DH, Yeung CK, Peter RM, Ibarra C, Gasser R, Itagaki K, et al. Isoform specificity of trimethylamine N-oxygenation by human flavin-containing monooxygenase (FMO) and P450 enzymes: selective catalysis by FMO3. Biochem Pharmacol. 1998;56(8):1005–12.
Wang Z, Klipfell E, Bennett BJ, Koeth R, Levison BS, Dugar B, et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature. 2011;472(7341):57–63.
Tang WH, Wang Z, Kennedy DJ, Wu Y, Buffa JA, Agatisa-Boyle B, et al. Gut Microbiota-Dependent Trimethylamine N-Oxide (TMAO) Pathway Contributes to Both Development of Renal Insufficiency and Mortality Risk in Chronic Kidney Disease. Circ Res. 2015;116(3):448–55.
Tang WH, Wang Z, Fan Y, Levison B, Hazen JE, Donahue LM, et al. Prognostic value of elevated levels of intestinal microbe-generated metabolite trimethylamine-N-oxide in patients with heart failure: refining the gut hypothesis. J Am Coll Cardiol. 2014;64(18):1908–14.
Tang WH, Wang Z, Shrestha K, Borowski AG, Wu Y, Troughton RW, et al. Intestinal microbiota-dependent phosphatidylcholine metabolites, diastolic dysfunction, and adverse clinical outcomes in chronic systolic heart failure. J Card Fail. 2015;21(2):91–6.
Tang WH, Wang Z, Levison BS, Koeth RA, Britt EB, Fu X, et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl J Med. 2013;368(17):1575–84.
Mendis S, Puska P, Norrving B, World Health Organization., World Heart Federation., World Stroke Organization. Global atlas on cardiovascular disease prevention and control. Geneva: World Health Organization in collaboration with the World Heart Federation and the World Stroke Organization; 2011. p. vi, 155.
Kruse JA, Carlson RW. Lactate metabolism. Crit Care Clin. 1987;3(4):725–46.
Phypers BPJ. Lactate physiology in health and disease. Continuing Education in Anaesthesia, Critical Care & Pain. 2006;6(3):128–32.
Ramakrishna B, Graham SM, Phiri A, Mankhambo L, Duke T. Lactate as a predictor of mortality in Malawian children with WHO-defined pneumonia. Arch Dis Child. 2012;97(4):336–42.
Chen YX, Li CS. Lactate on emergency department arrival as a predictor of mortality and site-of-care in pneumonia patients: a cohort study. Thorax. 2015;70(5):404–10.
Kim WY, Lee YJ, Yeon Lim S, Ok Koh S, Choi WI, Chan Kim S, et al. Clinical characteristics and prognosis of pneumonia and sepsis: multicenter study. Minerva Anestesiol. 2013;79(12):1356–65.
Rogers AJ, McGeachie M, Baron RM, Gazourian L, Haspel JA, Nakahira K, et al. Metabolomic derangements are associated with mortality in critically ill adult patients. PLoS One. 2014;9(1):e87538.
Belitz HD, Grosch W. Lehrbuch der Lebensmittelchemie. 3, u\0308berarbeitete Aufl. ed. Berlin. New York: Springer; 1987.
Foltran F, Gregori D, Caropreso A, Pagano E, Bruno A. Is blood glucose on admission a predictor of mortality in adult acute pneumonia? Clin Respir J. 2013;7(3):276–80.
McAlister FA, Majumdar SR, Blitz S, Rowe BH, Romney J, Marrie TJ. The relation between hyperglycemia and outcomes in 2,471 patients admitted to the hospital with community-acquired pneumonia. Diabetes Care. 2005;28(4):810–5.
Lepper PM, Ott S, Nuesch E, von Eynatten M, Schumann C, Pletz MW, et al. Serum glucose levels for predicting death in patients admitted to hospital for community acquired pneumonia: prospective cohort study. BMJ. 2012;344:e3397.
Trachootham D, Lu W, Ogasawara MA, Nilsa RD, Huang P. Redox regulation of cell survival. Antioxid Redox Signal. 2008;10(8):1343–74.
Forman HJ, Dickinson DA. Oxidative signaling and glutathione synthesis. Biofactors. 2003;17(1-4):1–12.
Biswas SK, Rahman I. Environmental toxicity, redox signaling and lung inflammation: the role of glutathione. Mol Aspects Med. 2009;30(1-2):60–76.
Rodas PC, Rooyackers O, Hebert C, Norberg A, Wernerman J. Glutamine and glutathione at ICU admission in relation to outcome. Clin Sci (Lond). 2012;122(12):591–7.
Huang CS, Chang LS, Anderson ME, Meister A. Catalytic and regulatory properties of the heavy subunit of rat kidney gamma-glutamylcysteine synthetase. J Biol Chem. 1993;268(26):19675–80.
Burgunder JM, Varriale A, Lauterburg BH. Effect of N-acetylcysteine on plasma cysteine and glutathione following paracetamol administration. Eur J Clin Pharmacol. 1989;36(2):127–31.
Swart KM, van Schoor NM, Lips P. Vitamin B12, folic acid, and bone. Curr Osteoporos Rep. 2013;11(3):213–8.
Fratoni V, Brandi ML. B Vitamins, Homocysteine and Bone Health. Nutrients. 2015;7(4):2176–92.
Herzenberg LA, De Rosa SC, Dubs JG, Roederer M, Anderson MT, Ela SW, et al. Glutathione deficiency is associated with impaired survival in HIV disease. Proc Natl Acad Sci U S A. 1997;94(5):1967–72.
Xiu LL, Lee MS, Wahlqvist ML, Chen RC, Huang YC, Chen KJ, et al. Low and high homocysteine are associated with mortality independent of B group vitamins but interactive with cognitive status in a free-living elderly cohort. Nutr Res. 2012;32(12):928–39.
Wong YY, Almeida OP, McCaul KA, Yeap BB, Hankey GJ, Flicker L. Homocysteine, frailty, and all-cause mortality in older men: the health in men study. J Gerontol A Biol Sci Med Sci. 2013;68(5):590–8.
Swart KM, van Schoor NM, Blom HJ, Smulders YM, Lips P. Homocysteine and the risk of nursing home admission and mortality in older persons. Eur J Clin Nutr. 2012;66(2):188–95.
Drewes YM, Poortvliet RK, Blom JW, de Ruijter W, Westendorp RG, Stott DJ, et al. Homocysteine levels and treatment effect in the PROspective Study of Pravastatin in the Elderly at Risk. J Am Geriatr Soc. 2014;62(2):213–21.
Waskiewicz A, Sygnowska E, Broda G. Homocysteine concentration and the risk of death in the adult Polish population. Kardiol Pol. 2012;70(9):897–902.
Naess H, Nyland H, Idicula T, Waje-Andreassen U. C-reactive protein and homocysteine predict long-term mortality in young ischemic stroke patients. J Stroke Cerebrovasc Dis. 2013;22(8):e435–40.
Vieira Ade L, Baptista A, Malho A, Pinho A, Silva AP, Bernardo I, et al. Homocysteine is a risk factor in predialysis patients when associated with malnutrition and inflammation. Int J Nephrol. 2010;2010:957645.
Holmsen H, Hindenes JO, Fukami M. Glycerophospholipid metabolism: back to the future. Thromb Res. 1992;67(3):313–23.
Sigruener A, Kleber ME, Heimerl S, Liebisch G, Schmitz G, Maerz W. Glycerophospholipid and sphingolipid species and mortality: the Ludwigshafen Risk and Cardiovascular Health (LURIC) study. PLoS One. 2014;9(1):e85724.
Drobnik W, Liebisch G, Audebert FX, Frohlich D, Gluck T, Vogel P, et al. Plasma ceramide and lysophosphatidylcholine inversely correlate with mortality in sepsis patients. J Lipid Res. 2003;44(4):754–61.
Bartke N, Hannun YA. Bioactive sphingolipids: metabolism and function. J Lipid Res. 2009;50(Suppl):S91–6.
Schlitt A, Blankenberg S, Yan D, von Gizycki H, Buerke M, Werdan K, et al. Further evaluation of plasma sphingomyelin levels as a risk factor for coronary artery disease. Nutr Metab. 2006;3:5.
Jiang XC, Paultre F, Pearson TA, Reed RG, Francis CK, Lin M, et al. Plasma sphingomyelin level as a risk factor for coronary artery disease. Arterioscler Thromb Vasc Biol. 2000;20(12):2614–8.
Steiber A, Kerner J, Hoppel CL. Carnitine: a nutritional, biosynthetic, and functional perspective. Mol Aspects Med. 2004;25(5-6):455–73.
Kalim S, Clish CB, Wenger J, Elmariah S, Yeh RW, Deferio JJ, et al. A plasma long-chain acylcarnitine predicts cardiovascular mortality in incident dialysis patients. J Am Heart Assoc. 2013;2(6):e000542.
Christ-Crain M, Stolz D, Bingisser R, Muller C, Miedinger D, Huber PR, et al. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med. 2006;174(1):84–93.
Van den Berghe G, de Zegher F, Bouillon R. Clinical review 95: Acute and prolonged critical illness as different neuroendocrine paradigms. J Clin Endocrinol Metab. 1998;83(6):1827–34.
Brambilla DJ, Matsumoto AM, Araujo AB, McKinlay JB. The effect of diurnal variation on clinical measurement of serum testosterone and other sex hormone levels in men. J Clin Endocrinol Metab. 2009;94(3):907–13.
Pan WH, Hung YT, Shaw NS, Lin W, Lee SD, Chiu CF, et al. Elderly Nutrition and Health Survey in Taiwan (1999-2000): research design, methodology and content. Asia Pac J Clin Nutr. 2005;14(3):203–10.
Norman PE, Flicker L, Almeida OP, Hankey GJ, Hyde Z, Jamrozik K. Cohort Profile: The Health In Men Study (HIMS). Int J Epidemiol. 2009;38(1):48–52.
Tekin AS, Sengul C, Kilicaslan B, Ozveren O, Kozdag G. The value of serum homocysteine in predicting one-year survival in patients with severe systolic heart failure. Turk Kardiyol Dern Ars. 2012;40(8):699–705.
No potential conflict of interest relevant to this systematic clinical review was reported.
Manuela Nickler and Manuel Ottiger contributed equally to this work.
About this article
Cite this article
Nickler, M., Ottiger, M., Steuer, C. et al. Systematic review regarding metabolic profiling for improved pathophysiological understanding of disease and outcome prediction in respiratory infections . Respir Res 16, 125 (2015). https://doi.org/10.1186/s12931-015-0283-6
- Lower respiratory tract infection
- Chronic obstructive pulmonary disease
- Mortality prediction
- Steroid hormones
- Biogenic amines
- Intermediates energy metabolism
- Oxidative status